Puliginurad (YL-90148) is a novel and potent urate transporter (URAT) inhibitor with the potential to be used for hyperuricemia and gout treatment.
Physicochemical Properties
| Molecular Formula | C19H16N2O2S |
| Molecular Weight | 336.407543182373 |
| Exact Mass | 336.093 |
| CAS # | 2013582-27-7 |
| PubChem CID | 122582049 |
| Appearance | White to off-white solid powder |
| LogP | 3.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 4 |
| Heavy Atom Count | 24 |
| Complexity | 519 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | C(C1SC2=CN=CC(C3C=CC(C#N)=CC=3)=C2C=1)C(C)(C)C(=O)O |
| InChi Key | QWCZAFGDQBUAFT-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C19H16N2O2S/c1-19(2,18(22)23)8-14-7-15-16(10-21-11-17(15)24-14)13-5-3-12(9-20)4-6-13/h3-7,10-11H,8H2,1-2H3,(H,22,23) |
| Chemical Name | 3-[4-(4-cyanophenyl)thieno[2,3-c]pyridin-2-yl]-2,2-dimethylpropanoic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References |
[1]. WHO Drug Information. International Nonproprietary Names for Pharmaceutical. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~130 mg/mL (~386.43 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 3.25 mg/mL (9.66 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 3.25 mg/mL (9.66 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: 3.25 mg/mL (9.66 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9726 mL | 14.8628 mL | 29.7256 mL | |
| 5 mM | 0.5945 mL | 2.9726 mL | 5.9451 mL | |
| 10 mM | 0.2973 mL | 1.4863 mL | 2.9726 mL |